
Opinion|Videos|November 1, 2024
SC vs IV Administration Methods
Key Takeaways
- Subcutaneous administration reduces healthcare resource utilization by minimizing administration time and facility requirements.
- Patient convenience with subcutaneous administration can enhance treatment adherence, particularly in chronic conditions.
Panelists discuss how subcutaneous (SC) administration of drugs like daratumumab offers advantages over intravenous (IV) administration in terms of reduced health care resource utilization, improved patient convenience, and potentially better treatment adherence, while also considering potential drawbacks such as injection site reactions and the need for proper training in SC administration techniques.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the pros and cons of subcutaneous compared with intravenous administration in terms of health care resource utilization, patient populations, and treatment adherence.
Advertisement
Related to this article

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Community Pharmacists Guide Patients New to Glucose Monitoring
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5


